Daniëlle van der Waal1, André L M Verbeek2, Gerard J den Heeten3, Theodora M Ripping2, Vivianne C G Tjan-Heijnen4, Mireille J M Broeders5. 1. 1 Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands Danielle.vanderWaal@radboudumc.nl. 2. 1 Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands. 3. 2 National Expert and Training Centre for Breast Cancer Screening, Nijmegen, The Netherlands 3 Department of Radiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 4. 4 Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. 5. 1 Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands 2 National Expert and Training Centre for Breast Cancer Screening, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Lifetime risks are often used in communications on cancer to the general public. The most-cited estimate for breast cancer risk (1 in 8 women), however, appears to be outdated. Here we describe the breast cancer burden in the Netherlands over time by means of lifetime and age-conditional risks. The aim is to identify changes in absolute risk of primary breast cancer diagnosis and death. METHODS: Data on breast cancer incidence, mortality and size of the female population were retrieved from the Netherlands Cancer Registry and Statistics Netherlands. Lifetime and age-conditional risks were calculated for 1990, 2000 and 2010 using the life-table method (DevCan software). RESULTS: The lifetime risk of developing breast cancer (ductal carcinoma in situ and invasive) in 1990, 2000 and 2010 was estimated at 10.8 (1 in 9.3 women), 13.5 (1 in 7.4) and 15.2% (1 in 6.6), respectively. Most women were still diagnosed after the age of 50, with the highest risk between 60 and 70 years in 2010. The lifetime risk of breast cancer death was 3.8% (1 in 27) in 2010, which is lower than in 1990 (4.5%; 1 in 22) and 2000 (4.2%; 1 in 24). CONCLUSION: Breast cancer risk has increased to 1 in 6.6 women being diagnosed during their lifetime (invasive cancer only: 1 in 7.4), whereas risk of breast cancer death has decreased from 1 in 22 to 1 in 27 women. To keep cancer management and prevention up-to-date, it remains important to closely monitor the ever-changing breast cancer burden.
BACKGROUND: Lifetime risks are often used in communications on cancer to the general public. The most-cited estimate for breast cancer risk (1 in 8 women), however, appears to be outdated. Here we describe the breast cancer burden in the Netherlands over time by means of lifetime and age-conditional risks. The aim is to identify changes in absolute risk of primary breast cancer diagnosis and death. METHODS: Data on breast cancer incidence, mortality and size of the female population were retrieved from the Netherlands Cancer Registry and Statistics Netherlands. Lifetime and age-conditional risks were calculated for 1990, 2000 and 2010 using the life-table method (DevCan software). RESULTS: The lifetime risk of developing breast cancer (ductal carcinoma in situ and invasive) in 1990, 2000 and 2010 was estimated at 10.8 (1 in 9.3 women), 13.5 (1 in 7.4) and 15.2% (1 in 6.6), respectively. Most women were still diagnosed after the age of 50, with the highest risk between 60 and 70 years in 2010. The lifetime risk of breast cancer death was 3.8% (1 in 27) in 2010, which is lower than in 1990 (4.5%; 1 in 22) and 2000 (4.2%; 1 in 24). CONCLUSION:Breast cancer risk has increased to 1 in 6.6 women being diagnosed during their lifetime (invasive cancer only: 1 in 7.4), whereas risk of breast cancer death has decreased from 1 in 22 to 1 in 27 women. To keep cancer management and prevention up-to-date, it remains important to closely monitor the ever-changing breast cancer burden.
Authors: Anouk J M Cornelissen; Melissa Kool; Tiara R Lopez Penha; Xavier H A Keuter; Andrzej A Piatkowski; E Heuts; René R W J van der Hulst; Shan Shan Qiu Journal: Breast Cancer Res Treat Date: 2017-03-07 Impact factor: 4.872
Authors: G T Vondeling; G L Menezes; E P Dvortsin; F G A Jansman; I R Konings; M J Postma; M H Rozenbaum Journal: BMC Cancer Date: 2018-03-07 Impact factor: 4.430
Authors: Marissa C van Maaren; Robert F Kneepkens; Joke Verbaan; Peter C Huijgens; Valery E P P Lemmens; Rob H A Verhoeven; Sabine Siesling Journal: PLoS One Date: 2019-01-24 Impact factor: 3.240
Authors: Daniël J van der Meer; Iris Kramer; Marissa C van Maaren; Paul J van Diest; Sabine C Linn; John H Maduro; Luc J A Strobbe; Sabine Siesling; Marjanka K Schmidt; Adri C Voogd Journal: Int J Cancer Date: 2020-12-16 Impact factor: 7.396
Authors: Siem A Dingemans; Peter D de Rooij; Roos M van der Vuurst de Vries; Leo M Budel; Caroline M Contant; Anne E M van der Pool Journal: Ann Surg Oncol Date: 2015-09-14 Impact factor: 5.344
Authors: Anouk J M Cornelissen; Jop Beugels; Sander M J van Kuijk; Esther M Heuts; Shai M Rozen; Aldona J Spiegel; René R W J van der Hulst; Stefania M H Tuinder Journal: Breast Cancer Res Treat Date: 2017-10-25 Impact factor: 4.872
Authors: Joost A G N Wolfs; Luuke G E H de Joode; René R W J van der Hulst; Shan S Qiu Journal: Breast Cancer Res Treat Date: 2019-09-21 Impact factor: 4.872
Authors: Inge M M Lakeman; Mar Rodríguez-Girondo; Andrew Lee; Rikje Ruiter; Bruno H Stricker; Sara R A Wijnant; Maryam Kavousi; Antonis C Antoniou; Marjanka K Schmidt; André G Uitterlinden; Jeroen van Rooij; Peter Devilee Journal: Genet Med Date: 2020-07-06 Impact factor: 8.864